Prior Ibrutinib May Improve CAR-T Efficacy in Rare Lymphoma

(MedPage Today) — Previous exposure to ibrutinib (Imbruvica) among patients with mantle cell lymphoma (MCL) was associated with improved efficacy after treatment with the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel…